Copy number, linkage disequilibrium and disease association in the FCGR locus by Yang, W et al.
Title Copy number, linkage disequilibrium and disease association inthe FCGR locus
Author(s)
Niederer, HA; Willcocks, LC; Rayner, TF; Yang, W; Lau, YL;
Williams, TN; Scott, JAG; Urban, BC; Peshu, N; Dunstan, SJ;
Hien, TT; Phu, NH; Padyukov, L; Gunnarsson, I; Svenungsson,
E; Savage, CO; Watts, RA; Lyons, PA; Clayton, DG; Smith, KG
Citation Human Molecular Genetics, 2010, v. 19 n. 16, p. 3282-3294
Issued Date 2010
URL http://hdl.handle.net/10722/125244
Rights
Copy number, linkage disequilibrium and disease
association in the FCGR locus
Heather A. Niederer1, Lisa C. Willcocks1, Tim F. Rayner1, Wanling Yang2, Yu Lung Lau2,
Thomas N. Williams3,4,5,6, J. Anthony G. Scott3,4, Britta C. Urban3,7, Norbert Peshu3,
Sarah J. Dunstan8,9, Tran Tinh Hien8, Nguyen Hoan Phu8, Leonid Padyukov10,
Iva Gunnarsson10, Elisabet Svenungsson10, Caroline O. Savage11, Richard A. Watts12,
Paul A. Lyons1, David G. Clayton1 and Kenneth G.C. Smith1,∗
1Cambridge Institute for Medical Research and Department of Medicine, University of Cambridge School of Clinical
Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0XY, UK, 2LKS Faculty of Medicine, Department of
Paediatrics and Adolescent Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China, 3Kenya
Medical Research Institute/Wellcome Trust Research Programme, Centre for Geographic Medicine Research, Kilifi,
Kenya, 4Nuffield Department of Medicine and 5Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK,
6INDEPTH Network, Accra, Ghana, 7Liverpool School of Tropical Medicine, Liverpool, UK, 8Oxford University Clinical
Research Unit, Wellcome Trust Major Overseas Program, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam,
9Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7LJ, UK,
10Rheumatology Unit, Department of Medicine at the Karolinska, University Hospital Solna, SE-17176 Stockholm,
Sweden, 11School of Infection and Immunity, College of Medical and Dental Sciences, University of Birmingham,
Birmingham B15 2TT, UK and 12School of Medicine, Health Policy and Practice, University of East Anglia, Norwich
NR4 7TJ, UK
Received February 11, 2010; Revised May 12, 2010; Accepted May 21, 2010
The response of a leukocyte to immune complexes (ICs) is modulated by receptors for the Fc region of IgG
(FcgRs), and alterations in their affinity or function have been associated with risk of autoimmune diseases,
including systemic lupus erythematosus (SLE). The low-affinity FcgR genomic locus is complex, containing
regions of copy number variation (CNV) which can alter receptor expression and leukocyte responses to IgG.
Combined paralogue ratio tests (PRTs) were used to distinguish three intervals within the FCGR locus which
undergo CNV, and to determine FCGR gene copy number (CN). There were significant differences in FCGR3B
and FCGR3A CNV profiles between Caucasian, East Asian and Kenyan populations. A previously noted
association of low FCGR3B CN with SLE in Caucasians was supported [OR 5 1.57 (1.08–2.27), P 5 0.018],
and replicated in Chinese [OR 5 1.65 (1.25–2.18), P 5 4 3 1024]. There was no association of FCGR3B CNV
with vasculitis, nor with malarial or bacterial infection. Linkage disequilibrium (LD) between multi-allelic
FCGR3B CNV and SLE-associated SNPs in the FCGR locus was defined for the first time. Despite LD between
FCGR3B CNV and a variant in FcgRIIB (I232T) which abolishes inhibitory function, both reduced CN of
FCGR3B and homozygosity of the FcgRIIB-232T allele were individually strongly associated with SLE risk.
Thus CN of FCGR3B, which controls IC responses and uptake by neutrophils, and variations in FCGR2B,
which controls factors such as antibody production and macrophage activation, are important in SLE patho-
genesis. Further interpretations of contributions to pathogenesis by FcgRs must be made in the context of
LD involving CNV regions.
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INTRODUCTION
The low-affinity receptors for the Fc region of IgG, FcgRII
and FcgRIII, play a key role in regulation of the immune
response to IgG. Following cross linking of the receptors by
immune-complexed antigen, they are important in phagocyto-
sis and presentation of complexed antigen, as well as in
responses such as cytokine production. The FcgRs are predo-
minantly activatory, with the exception of the FcgRIIB recep-
tor which has an inhibitory effect on signalling through the
activatory FcgRs as well as the B cell receptor (1).
The human 1q23.3 locus contains five FCGR genes
(FCGR2A, FCGR2B, FCGR2C, FCGR3A and FCGR3B)
encoding the FcgRII and FcgRIII receptor families. There is
high sequence similarity between the genes, in part due to an
ancestral segmental duplication, which produced FCGR3B
and formed the pseudogene FCGR2C from copies of the 5′
end of FCGR2B and the 3′ end of FCGR2A (2). The duplicated
regions are 98% identical (3), and arose following the division
of the great apes from the new world monkeys (4,5). The locus
is complicated by the presence of more recent, .99% identical,
copy number variable (CNV) regions, the exact limits and
number of which have not been conclusively defined (6–8).
The homology in the region of the ancestral duplication is
likely to facilitate CNV formation (9).
Polymorphisms in the low-affinity FcgRs have been associ-
ated with a variety of autoimmune diseases, foremost among
them systemic lupus erythematosus (SLE). SLE is clinically
diverse, but is unified by autoantibody production, deposition
of immune complexes (ICs) in organs including the joints,
skin and kidneys, and a subsequent inflammatory response to
the deposited ICs. The inflammation in these organs results
in tissue damage leading to a diverse range of clinical features,
from skin rashes and cytopenias through to organ-threatening
glomerulonephritis (10). Failure of FcgR-mediated clearance
of ICs and control of inflammatory responses are thought to
be a predisposing factor to SLE.
Alterations in the function of FcgRs have been associated
with SLE. A substitution in FcgRIIA where histidine replaces
arginine at position 131 (R131H, rs1801274) increases the affi-
nity of binding to IgG2 (11), and increases phagocytosis of IgG2
opsonin. In FcgRIIIA, a valine for phenylalanine substitution
(V176F, rs396991) lowers affinity for IgG1 and IgG3, and pre-
vents binding to IgG4 (12). Two isoforms of FcgRIIIB are
encoded by haplotypes of four SNPs: the FcgRIIIB-HNA1a
isoform has reduced N-linked glycosylation compared with
the FcgRIIIB-HNA1b isoform, and has increased affinity for
IgG3, mediating increased phagocytosis of IgG1 and IgG3
ICs (13). The low-affinity alleles of all three receptors have
been linked to risk of SLE in linkage and association studies
(14). The presence of CNV regions can lead to apparent viola-
tion of Hardy–Weinberg equilibrium, and can lead to exclusion
of probes binding within these regions from genome-wide
association studies (GWAS) (8). This may be the reason that
only FcgRIIA-131R, and not SNPs in FcgRIIIB and FcgRIIIA,
was identified as associated with SLE by GWAS (15).
The disruption of the inhibitory function of FcgRIIB due to
the conversion of an isoleucine to a threonine in the transmem-
brane domain of the inhibitory receptor (I232T, rs1050501)
(16) is also associated with SLE in Asians (17) and Caucasians
(18). This appears to be due to a failure of the threonine form
of the receptor (FcgRIIB-232T) to partition to lipid rafts,
perhaps due to the polar nature of the threonine, or disruption
of a protein sequence necessary for raft entry (16,19). Exclu-
sion from lipid rafts abolished the inhibition of activatory sig-
nalling initiated by crosslinking of FcgRIIIB and the
activatory FcgR or B cell receptor by IC (16).
Copy number (CN) variable areas may cover 5% of the
genome, and contribute to the genetic variation between indi-
viduals (7). CN of the low-affinity FCGR genes and the
association of CN with disease have recently been investi-
gated. Studies using multiplex ligand probe amplification
(MLPA) have investigated gene CN across the locus in Cauca-
sians (6,20). qPCR methods have also been used to determine
CN of FCGR3B alone in Caucasians (21–24) or in Chinese
(23,25). In these studies, low CN of FCGR3B was associated
with SLE (22,23) or SLE nephritis (21) in Caucasians,
although both low and high CN was also recently associated
with SLE (24) and no association with SLE was reported in
Chinese (23,25). These studies are limited, however, by the
requirement to categorize the continuous distribution of data
generated by qPCR assays into discrete CN ‘bins’ (21,22,24)
or alternatively to compare the means (23). The limitations
of the qPCR method may also be responsible for the wide dis-
crepancy between the percentage of Caucasian individuals
with low FCGR3B CN determined by qPCR [approximately
10–25% (22), and 40% (21)] and MLPA methods (5–7%)
(6,20). A more accurate method of CN designation is therefore
needed to confirm the association with SLE.
It is important to clarify the effect of FCGR3B CN in disease,
and determine if it is independent of the effect of other poly-
morphisms in the locus. In this study, we used an assay combin-
ing three paralogue ratio tests (PRTs) to define three CNV
regions within the FCGR locus, and determine the prevalence
of variation of these regions in Caucasian, East Asian and
Kenyan populations. Further, the previous association of low
FCGR3B CNV in SLE in Caucasians was supported, and an
association with SLE was identified in a second ethnic group,
Hong Kong Chinese. We describe differences in linkage dise-
quilibrium (LD) in the FCGR region between ethnic groups
for the SLE-associated SNPs and with FCGR3B CNV, while
taking into account FCGR3A CNV. We show that although
there is LD between FCGR3B CN and FCGR2B-I232T, both
show an independent effect on SLE risk.
RESULTS
Copy number in the FCGR locus
The qPCR-based CNV assays previously used to interrogate
the FCGR locus (21–25) have been shown to be limited by
the requirement to make discrete CN calls from continuous
data distributions (23,26). Therefore, we developed an assay
involving a combination of three PRTs to better analyse
CNV in the FCGR locus. Both PRT and qPCR compare the
signal generated at a variable locus to that at a reference
locus. The ratio between amplified products, and thus relative
gene CN, can then be determined. The key advantage to the
PRT assay is that a single pair of primers amplifies two
genomic loci, producing products which differ in size by a
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few nucleotides, in the same tube. In contrast, in qPCR, the
separate reference and CNV reactions introduce variability,
with significant plate-to-plate variation (23). Two PRT
assays developed in this study compare the CN of a region
in FCGR3B with one in FCGR3A, and CN of a region in
the FCGR2C 3′-untranslated region (3′-UTR) with one in
the FCGR2A 3′-UTR (Fig. 1, Supplementary Material,
Fig. S1A and B). These were used in conjunction with a
third previously described PRT assay which compared total
CN in both FCGR3B and FCGR3A with a region on Chromo-
some 18 (27). Comparison of these three PRT assays allowed
CN of FCGR3A, FCGR3B and the 3′-UTR of FCGR2A and
FCGR2C to be determined, without the requirement of a
restriction enzyme digest as used previously (27) (full descrip-
tion of PRT in Supplementary Material; Figs S1 and S2).
FCGR2B was previously shown not to undergo CNV (6,20).
The CN variation over these loci suggested at least three
CNV regions: CNR1, CNR2 and CNR3 (Fig. 1, Supplemen-
tary Material, Fig. S1C and D). The more common CNR1
and CNR2 show similarity to, and extend, previously ident-
ified CNV regions (6,20), and a novel CNR3 is seen primarily
in East Asians. Both duplication and deletion were observed at
CNR1 and CNR2 (and thus the CNV at these sites is multi-
allelic), whereas only a duplication of CNR3 was able to be
identified (Supplementary Material, Fig. S2E and Table S1).
Variation in FCGR CNV between ethnic groups
Previous work, based on a small number of individuals, raised
the possibility of ethnic variation in FCGR CN profiles (27).
To investigate this, the triple PRT assay was used to determine
CN of FCGR3B and FCGR3A in large cohorts of Caucasian,
Hong Kong Chinese, Vietnamese Kinh and Kenyan individuals
(Fig. 2). There was significant ethnic variation in the CN profiles
for both FCGR3B and FCGR3A. Low FCGR3B CN (0 or 1
copies) was least common in Caucasians, intermediate in
Chinese and Vietnamese populations and highest in the Kenyan
population. FCGR3B high CN (3 or more copies) was most
common in theChinese andVietnamese populations. The percen-
tage of Caucasian individuals with FCGR3B low CN (7.4%) is
similar to the 5–7% previously found using MPLA and an
assay combining PRT, restriction enzyme digest and short term-
inal repeat amplification to determineCN(6,27) and considerably
lower than the 10–40% found using qPCR (21,22). Overall, there
was less variation in FCGR3A CN, with high CN more common
than low. FCGR3A 3CN was most common in the Vietnamese
population, and least common in Kenyans.
Low CN of FCGR3B is associated with SLE, but not
with vasculitis
Previous studies, using qPCR methodology, had shown associ-
ation of low CN of FCGR3B with SLE nephritis (21,22) and
SLE (22,23) in Caucasians but not Asians (23,25). These find-
ings are complicated by a recent qPCR study which showed
that individuals with low and high CN were both increased
in an SLE cohort (24).
Therefore, we analysed FCGR CNV in cohorts of SLE
patients and controls using the triple PRT assay (Fig. 3A).
The association with low CN, but not high CN, was supported
by Caucasian SLE cohorts from the UK and Sweden. These
cohorts individually showed a trend for increased low CN
with SLE (Fig. 3A) and combined as a single cohort by
meta-analysis (Fig. 3B) showed significant association of
Figure 1. CNV and paralogue ratio test (PRT) in the FCGR l ocus. A segmental duplication resulted in the production of FCGR3B, as well as FCGR2C which
combines the 5′ end of FCGR2B and the 3′ end for FCGR2A. Repeated black, grey and white regions reflect areas of homology within the genes. The PRT primer
pairs used in this study to determine copy number variation (CNV) are PRT-2C3
′
/2A3
′
(circle) and PRT-3B/3A (square), which each bind at and amplify two
locations in the genome on Chromosome 1; and PRT-3(A+B)/Chr18 (triangle) which binds at three locations—two on chromosome 1 and one on chromosome
18. Relative gene locations are derived from the Database of Genomic Variants, human genome build 36 (hg18). Three CNV regions are identified by variation at
PRT primer binding sites (marked): CNR1 (blue) includes CNV at the PRT primer sites in FCGR2C and FCGR3B; CNR2 (red) includes CNV at the PRT primer
sites in FCGR2A 3′-UTR and FCGR3A, but not in FCGR2C 3′-UTR; and CNR3 (green) includes CNV at the PRT primer sites in FCGR3A and FCGR2C 3′-UTR.
Solid colour bars indicate areas suggested to be included in the CNV interval and thin grey lines indicate maximum plausible extent. Diploid copy number
variations of each region observed in this study are noted, with other probable variations in brackets. For further details of the relationship between relative
PRT product, underlying gene CN and CNV regions, see Supplementary data online.
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low CN with SLE [odds ratio (OR) 1.57, 95% confidence
interval (CI) 1.08–2.27; P ¼ 0.018]. We also tested the
association of low CN of FCGR3B with SLE in a Hong
Kong Chinese cohort, and found a strong association of low
CN with SLE (OR 1.65, 95% CI 1.25–2.18; P ¼ 4 × 1024)
with a similar effect size to that in Caucasians (Fig. 3A),
despite previous qPCR studies which found no association in
different Chinese cohorts (23,25). This association was the
strongest in the sub-group of Chinese patients with lupus
nephritis, and demonstrates for the first time the association
of FCGR3B low CN with SLE in a non-Caucasian population.
The combined OR of this effect, by meta-analysis, was 1.62
(95% CI 1.30–2.03) (Fig. 3B). Thus FCGR3B low CN is
one of the strongest common variants reported to increase
risk of SLE (28). The amount of FCGR3A CNV did not
vary significantly between SLE cases and controls (Sup-
plementary Material, Table S2).
We also investigated the association of FCGR3B CN with
anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV). AAV is a systemic autoimmune disease
distinct from SLE, with anti-neutrophil cytoplasmic anti-
bodies, but not with IC deposition. An initial association
with AAV and low FCGR3B CN by qPCR (22) was not
confirmed (23). We thus used the triple PRT assay to
analyse the CNV of a combined UK Caucasian vasculitis
cohort, and showed no difference in the CN profile com-
pared with controls (Fig. 3C), suggesting that the initial
finding may have been a false positive resulting from incon-
sistencies in the qPCR assay.
No association of FCGR3B CN with malaria
or bacterial sepsis
FCGR3B is primarily expressed on neutrophils and FCGR3A
on monocytes and macrophages. Both are likely to play a
role in the defence against infection. We investigated
whether CN of either FCGR3B or FCGR3A influences risk
of developing severe malaria in Vietnamese and Kenyan popu-
lations from areas with endemic malaria. The higher incidence
of SLE-associated low FCGR3B CN in the Kenyan population
may be due to positive selective pressure by conferring protec-
tion from infectious disease. In Africa, endemic malaria is a
major contributor to mortality in children (29), and malaria
is known to exert a strong evolutionary selective effect (30).
The FCGR CN profiles of two Kenyan cohorts comprised of
children treated for severe malaria at Kilifi District Hospital
were compared with cord blood controls. In neither of the
Kenyan cohorts, nor in a cohort of Vietnamese adults treated
for severe malaria, was there any association of CN of
FCGR3B (Fig. 4) or FCGR3A (Supplementary Material,
Table S2).
Severe bacterial sepsis is also a major factor in child mor-
tality in Africa (29). We investigated FCGR3B and FCGR3A
CN in a cohort of children admitted to Kilifi District Hospital
with blood-culture positive bacterial infection. The cohort was
heterogeneous with respect to infecting bacteria, but those
detected most frequently were Streptococcus pneumoniae,
Salmonella typhi, Haemophilus influenzae and Escherichia
coli. There was no difference in the CN profiles of FCGR3B
Figure 2. Ethnic differences in FCGR3B and FCGR3A CN profiles. (A) Distribution of copy number of FCGR3B in four control cohorts from different ethnic
backgrounds. The Caucasian controls are from the UK cohort. Statistical differences between the populations are tested for FCGR3B diploid copy number ,2 or
.2 versus the remainder, and the P-value for a Fisher’s exact test is shown. (B) Distribution of copy number of FCGR3A in the four control cohorts from differ-
ent ethnic backgrounds. Statistical differences between the populations are tested for 1 versus 2,3 diploid copy number, and the significance for a Chi-squared test
of independence (df ¼ 2) is shown. Bold values show the significant P-value.
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in this cohort compared with controls (Fig. 4). There was,
however, a weak association between high FCGR3A CN and
disease (OR 1.92, 95% CI 1.03–3.56; P ¼ 0.039) (Sup-
plementary Material, Table S2).
Confirmation of association of FcgRIIB-232T
homozygosity with SLE in Caucasians
Homozygosity of the allele for the FcgRIIB-232T isoform has
previously been associated with SLE, initially in East Asians
(17) and more recently in Caucasians (18). We have added
to this data by analysing two new Caucasian SLE cohorts
from UK and Swedish populations, further demonstrating a
significant association of FcgRIIB-232T allele homozygosity
with SLE risk (Supplementary Material, Table S3). When all
studies involving Caucasian cohorts were analysed in a
meta-analysis, there was a strong association with SLE (OR
2.26, 95% CI 1.49–3.41) (Supplementary Material, Fig. S3).
The Hong Kong Chinese cohort had previously been typed
for the FcgRIIB-I232T polymorphism, and showed a non-
significant trend towards an increased percentage of
FcgRIIB-232T allele homozygotes in SLE, which strength-
ened the overall association by meta-analysis in East Asian
cohorts (18).
Figure 3. Association of FCGR3B CN with SLE and vasculitis. (A) Distribution of copy number of FCGR3B in three systemic lupus erythematosus (SLE) case
cohorts compared with their controls: UK Caucasian, Swedish (SW) Caucasian and Hong Kong (HK) Chinese. The HK Chinese cases were subsequently split
into those with (+neph) and without (2neph) nephritis. Numbers of individuals in each cohort are noted. Statistical significance for a difference between cases
and controls was tested for FCGR3B diploid copy number of ,2 or .2 versus the remainder by a Fisher’s exact test. OR, odds ratio (95% confidence interval);
P, significance value. Bold values show the significant P-value. (B) Meta-analysis (random effects model) of ,2 versus 2,3 and 4 diploid copies of FCGR3B
between SLE cases and controls in all three SLE cohorts (main graph) or Caucasian cohorts alone (bar on right). Box size is proportional to sample size. (C)
Distribution of copy number of FCGR3B in an ANCA-associated vasculitis (AAV) Caucasian cohort and controls. Controls included those used as controls for
the UK SLE cohort.
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LD between the FCGR2B-I232T polymorphism
and FCGR3B CN
It was thought important to determine the degree of LD
between the multi-allelic FCGR3B CNV and the
FcgRIIB-I232T polymorphism, as these neighbouring variants
are both associated with SLE risk. Indeed, our initial obser-
vations showed that low FCGR3B CNV was more common
in individuals with the FcgRIIB-232T isoform, suggesting
that these SLE-associated alleles might be inherited together
to some degree (Supplementary Material, Fig. S4). This
raised the possibility that the observed disease association
attributed to one variant may be primarily due to the other
variant. LD between the FcgRIIB-I232T SNP and FCGR3B
CNV was determined in control cohorts both at the haplotype
level, using estimated phased haplotypes, as well as at the gen-
otype level. There was weak-to-moderate LD in the Caucasian
and Chinese control cohorts, as measured by D′, which varied
depending whether LD calculation compared the deletion hap-
lotype or the duplication haplotype to the remainder (Fig. 5,
Supplementary Material, Table S4).
LD between other FCGR SNPs and FCGR3B CN
Multiple SNPs within the low-affinity FCGR locus are associ-
ated with SLE. This further raises the question of whether all
the disease-associated variants act independently, or whether
LD across the locus influences these reported associations.
Therefore, we also typed the FcgRIIA-R131H and
FcgRIIIA-V176F polymorphisms in a subset of the SLE
cohorts (Supplementary Material, Table S5), and in the
Kenyan and Vietnamese control cohorts (Supplementary
Material, Table S6). The proportion of FcgRIIA-131R homozy-
gotes was increased in the SLE cohorts, although the association
was not significant, perhaps due to relatively small numbers
(Supplementary Material, Table S5). In both the Chinese and
Caucasian SLE cohorts, the OR was 1.3, which correlated
with that noted in two SLE GWAS (15,31). FcgRIIIA-V176F
did not show a significant association with SLE.
There is some evidence that there is LD between the
SLE-associated SNPs FcgRIIB-I232T and FcgRIIA-R131H
or FcgRIIIA-V176F in East Asian populations (32–34), and
between FcgRIIA-R131H and FcgRIIIA-V176F in European
Caucasian populations and an African American population
(35–37). In these studies, however, CN of FCGR3A has not
been taken into account, and, to our knowledge, no formal
assessment of LD between SLE-associated SNPs and CNV
in the FCGR locus has been performed. We investigated the
degree of LD between SLE-associated SNPs FcgRIIB-I232T,
FcgRIIA-R131H, FcgRIIIA-V176F and FCGR3B CN, con-
trolling for FCGR3A CN. LD based on genotype and phase
haplotype data was generally consistent (Supplementary
Material, Table S4). The pattern of LD between SNPs
observed in our Caucasian and East Asian control cohorts
(Fig. 5) generally corresponded to that seen in previous
studies. In addition, LD between FcgRIIB-I232T and
FcgRIIA-R131H or FcgRIIIA-V176F was noted in the
Kenyan control cohort. There was also some LD between
FCGR3B CNV and FcgRIIA-R131H in the Chinese control
cohort; however, it was the combination of SLE-associated
FcgRIIA-131R homozygosity and protective FCGR3B high
CN that was enriched, suggesting the risk due to a low
FCGR3B CNV was not due to a linked FcgRIIA-131R allele
(Supplementary Material, Fig. S4 and Table S7).
Low FCGR3B CNV and FcgRIIB-232T both contribute
to SLE risk despite LD
Given the presence of LD between the FcgRIIB-I232T and
FCGR3B CNV loci, we investigated whether low FCGR3B
CNV contributed to the risk of SLE independent of the
effect of FcgRIIB-232T. The SLE and control cohorts were
stratified by FcgRIIB-I232T genotype and the association of
Figure 4. No association of FCGR3B CN with malaria or bacterial sepsis. Distribution of copy number of FCGR3B in four case cohorts compared with cord
blood controls. A single Kenyan control group is used for all three Kenyan case cohorts. Numbers of individuals in each cohort are noted. Statistical significance
for a difference between cases and controls are tested for FCGR3B diploid copy number of ,2 or .2. P, significance value for a Fisher’s exact test.
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low FCGR3B CNV after accounting for FcgRIIB-I232T back-
ground was determined in the Chinese and the combined Cau-
casian cohorts. In both populations, the significantly increased
risk associated with low FCGR3B CNV was only observed in
the presence of the FcgRIIB-232T allele, although a non-
significant trend was seen in the FcgRIIB-232I homozygotes
(Table 1). Numbers were too small in the FcgRIIB-232T
homozygote group for meaningful analysis alone. The vari-
ation according to FcgRIIB-232T allele presence could indi-
cate a modifying effect of FcgRIIB-I232T on the risk due to
low FCGR3B CNV. Because there was LD between the loci,
it was not possible to differentiate between whether the rela-
tive risk of the CNV was altered by the FcgRIIB-232T
allele in a cis (within the same haplotype) or a trans (inherited
independently on different chromosomes) manner. A test for
heterogeneity of ORs across the FcgRIIB-I232T strata,
however, was not significant in either cohort.
To further test whether each locus contributed to risk of SLE
once the effect of the other was taken into account, we analysed
the effect of FCGR3B CNV and the FcgRIIB-I232T SNP by
logistic regression to a general linear model in the Chinese
and Caucasian cohorts. After adjusting for effects due to differ-
ences between two Caucasian cohorts, the effect of FCGR3B
CNV was significant after accounting for the effect due to
FcgRIIB-I232T (Table 2). Equally, the effect of FcgRIIB-I232T
was significant after adjusting for the effect due to FCGR3B
CNV. In the Hong Kong Chinese cohort, the effect of
FCGR3B CNV was also significant after accounting for the
effect due to FcgRIIB-I232T, although the trend for the
FcgRIIB-I232T SNP did not reach significance. There was no
significant deviation from a multiplicative model of risk for
the SNP:CNV interaction in the Chinese cohort, and it was
only just significant in the Caucasian cohort. Overall, this indi-
cated that, despite the presence of LD between the loci,
FCGR2B-I232T and FCGR3B CNV have independent effects
on the risk of developing SLE. The risk associated with low
FCGR3B CN is equivalent between two ethnic groups. We
therefore demonstrate a consistent, strong effect of low
FCGR3B CN on the risk of developing SLE.
DISCUSSION
Using a triple PRT assay, we have confirmed association of
low CN of FCGR3B with SLE. Although the association in
Caucasians was previously reported, this triple PRT assay
Figure 5. Linkage disequilibrium (LD) in the FCGR locus. LD in normal individuals between FCGR3B copy number variation (CNV) and single nucleotide
polymorphisms (SNPs) previously associated with systemic lupus erythematosus (SLE) was determined by haplotype-based methods (D′) and genotype-based
methods [correlation (Gcor) and covariance (Gcov)]. Colours indicate increasing level of LD. Split colour bars indicate variation in LD when either high or low
FCGR3B CN was compared. #Combined genotype involving two SLE risk diplotypes (FCGR2A-131R/R, FCGR3A-176F/F, FCGR2B-232T/T, or FCGR3B-low
CN) is enriched. ∗Combined genotype involving one SLE risk and one non-risk diplotype is enriched. All individuals are from the control cohorts used in associ-
ation studies.
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allows clearer designation of integer values for CN. The
association found in Hong Kong Chinese is novel, and is
important as it validates the effect of FCGR3B CN in a differ-
ent genetic background. The highest ORs for risk of SLE of
the common polymorphisms strongly associated by GWAS
are the major histocompatibility complex region (OR ¼ 2.0),
interferon regulatory factor 5 (IRF5, OR ¼ 1.8) and comp-
lement receptor 3 subunit integrin alpha M (ITGAM OR ¼
1.6) (15). This places the OR for FCGR3B low CN, at 1.6,
among the strongest genetic risk factors yet identified for SLE.
FcgRIIIB is expressed primarily on neutrophils, where it is
the most common FcgR (38,39). The strong association of low
CN of FCGR3B with SLE suggests a hitherto un-emphasized
role of neutrophils in protection from SLE. Defects in IC
clearance have been implicated in SLE, and macrophages
from SLE patients show reduced soluble IC uptake (40,41).
Neutrophils lacking FcgRIIIB had profoundly reduced
soluble IC uptake, and increasing FCGR3B CN correlated
with FcgRIIIB surface expression and increasing IC uptake
(23). FcgRIIIB is also important in tethering neutrophils
under flow conditions, which is required to allow extravasation
into the tissues (42,43); such adhesion correlated with
FCGR3B CN (23). FcgRIIIB appears less important in initiat-
ing superoxide release, since increased FCGR3B CN in indi-
viduals within a family did not cause significantly increased
release upon stimulation (23). A contribution to IC clearance
may be made by neutrophils trafficking to sites of IC depo-
sition and clearing complexes once there. Reduced FcgRIIIB
expression could thus lead to increased IC deposition and
resulting inflammatory damage and disease.
FcgRIIIB is attached to the cell membrane by a glycosyl-
phosphatidylinositol (GPI) anchor, and does not contain intrin-
sic cytoplasmic signalling domains or associate with signalling
adaptor proteins used by other FcgRs. Instead, it is thought to
colocalize with and signal through other receptors, such as
complement receptor 3 (CR3) and FcgRIIA, to facilitate neu-
trophil functions such as phagocytosis and the oxidative burst
(44–48). Therefore, it is interesting to note that polymorphisms
in ITGAM (part of the CR3 receptor) and FCGR2A are
strongly associated with SLE in GWA studies (15,31).
Although in this study no interaction was found by logistic
regression between the FCGR2A SLE-associated SNP and
FCGR3B CN, an interaction with ITGAM was not tested.
Since CR3 is important in FcgRIIIB-mediated phagocytosis
in neutrophils (46), it is possible that polymorphisms which
inhibit CR3 binding to complement or interaction with
FcgRIIIB may exacerbate the effect of low FCGR3B CN.
CN of FCGR2C alters in parallel with both FCGR3A and
FCGR3B in the CNV regions. FCGR2C is a pseudogene in
the majority of individuals. In a Caucasian population,
however, 18% of individuals had at least one FCGR2C
allele with an open reading frame, due to a variant which
changes the common stop codon in exon 3 to a glutamine
(6). The expression level of FCGR2C on NK cells correlates
to presence of this open reading frame allele, rather than
total gene CN (6). Although there was an association of
FCGR2C-ORF frequency with risk of idiopathic thrombocyto-
penic purpura, there was no association with total CN of
FCGR2C (6). The increase in FCGR2C concomitant with
FCGR3B in the SLE population in our study is therefore unli-
kely to correlate to increased FCGR2C expression.
This study also highlights the complexity of the low-affinity
FCGR locus. In large cohorts from multiple ethnic groups, we
were able to identify multiple individuals with variation in two
different CNV regions. A third CNV region (CNR3) primarily
found in East Asian populations was also identified which,
although it included FCGR3A and FCGR2C, had altered
breakpoints compared to the more common CNR2 region. It
is likely that there are multiple breakpoints of CNV regions
within the areas of homology in this locus.
A previous study has examined LD of FCGR3B CNV or
FcgRIIIB-HNA1 polymorphisms with proximal SNPs in
HapMap individuals, and found no SNPs with sufficiently
high LD (assessed by r2) to be predictive, although the
study was limited by the SNP data available and did not
include any SNPs within the ancestral duplication of FCGR
Table 1. FCGR3B CN stratified by FCGR2B-I293T type
FCGR3B CN UK and Swedish Caucasiana P-value Hong Kong Chinese P-value
SLE, n Cont, n OR (95% CI) SLE, n Cont, n OR (95% CI)
418 595 FCGR2B-232 all 745 914 FCGR2B-232 all
0,1 49 45 1.55 (1.02–2.37) 0.049 117 89 1.73 (1.29–2.32) 3 3 1024
3,4 43 66 0.93 (0.62–1.39) 0.76 100 134 0.90 (0.68–1.19) 0.48
297 472 FCGR2B-232 I/Ib 432 495 FCGR2B-232 I/I
0,1 28 33 1.35 (0.79–2.28) 0.28 48 44 1.29 (0.84–1.99) 0.27
3,4 32 59 0.86 (0.55–1.36) 0.57 73 87 0.95 (0.68–1.34) 0.79
89 106 FCGR2B-232 I/T 260 366 FCGR2B-232 I/T
0,1 15 6 2.98 (1.11–8.00) 0.037 55 37 2.39 (1.52–3.75) 1 3 1024
3,4 7 6 1.39 (0.45–4.29) 0.58 26 43 0.83 (0.50–1.40) 0.52
32 17 FCGR2B-232 T/T 53 53 FCGR2B-232 T/T
0,1 6 6 0.53 (0.15–1.90) 0.34 14 8 2.02 (0.77–5.32) 0.2
3,4 4 1 2.13 (0.22–20.6) 0.65 1 4 0.24 (0.03–2.18) 0.36
Breslow–Day test of heterogeneity 0.056 0.14
CN, copy number (diploid); SLE, systemic lupus erythematosus; cont, control; OR, odds ratio; CI, confidence interval.
aCombined Caucasian group: the sum of UK Caucasian and Swedish Caucasian cohorts.
bFCGR2B-232 I/I, FCGR2B-232 I/T, or FCGR2B-232 T/T indicates the stratification of the data before the association of ,2 or .2 diploid copies of FCGR3B
with SLE is tested by Fisher’s exact test. All individuals are FCGR3A CN ¼ 2.
Bold values show the statistical significance at the 95% level.
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genes (27). Others have assessed LD between SNPs and
di-allelic CNVs (7). We examined linkage between the multi-
allelic FCGR3B CNV and SLE-associated SNPs in East Asian,
Caucasian and Kenyan control cohorts, and demonstrated
weak-to-moderate LD in the FCGR locus. The differing
degree of LD between FCGR2B and FCGR3B found when
comparing the FCGR3B deletion haplotype or the duplication
haplotype may indicate that these events formed indepen-
dently, and may have subtly different breakpoints.
The FCGR2B-I232T polymorphism was found to be in LD
with FCGR3B CNV in Chinese and Caucasians. The associ-
ation of homozygosity of the FcgRIIB-232T allele with SLE
has been well established in East Asian populations
(17,18,49), and in this study we confirm our previously
reported association in Caucasians (18) with an effect size
(OR ¼ 2.6) among the highest for SLE. Critically, FCGR3B
CNV was demonstrated to independently contribute to SLE
risk despite the LD with FCGR2B-I232T.
There were two intriguing negative findings in this study. The
first was that there was no association with AAV. The evidence
for association of FCGR3B CN with vasculitis has been contra-
dictory—low CN was initially associated with disease (22), but
this finding was not replicated in a second study using a similar
qPCR assay (23). In the current study, we found no association
or distinct trend in either direction. It is plausible that FCGR3B
low CN does not have a significant effect on AAV, since ICs
are not thought to play a major role in AAV pathogenesis
(50). The previous association with low AAV depended upon
integer CN designation from a qPCR assay, and the number
of low CN individuals in Caucasian controls was high (10–
25%) compared to what has been identified here with the
triple PRT (7%) and previously with MLPA (5–7%) (6,20).
Thus findings based solely on qPCR assays must be treated
with caution, and confirmed using other methods.
There was no association of FCGR3B CN with severe bac-
terial infection or malaria in Kenyan and Vietnamese cohorts.
Neutrophils are known to play a critical role in the clearance
of bacteria. However, it is possible that a dosage effect of
FcgRIIIB is not equally important in all infections. In the
response to bacteria which elicit a largely IgG2 response,
such as Streptococcus pneumoniae, FcgRIIA-H131 is most
effective in binding the IgG isotype (14) and will be most
important in binding the opsonized pathogen, whereas
FcgRIIIB binding may play a lesser role. Thus to examine
the effect of FCGR3B CN on such diseases, the analysis of
larger and microbiologically more precisely defined cohorts
will be required.
This study describes a triple PRTmethod to determine integer
CN of genes in the FCGR locus, in particular FCGR3B. The
heterogeneity of CNV breakpoints is highlighted, as is LD
between SNPs and CNV in the region, and future studies in the
FCGR locus will need to take this complexity into account. In
this study, CN of FCGR3B is demonstrated to be an important
risk factor in SLE across two different ethnic groups, indepen-
dent of neighbouring FCGR SNPs. Further work needs to be
carried out to accurately determine the profile of FCGR3B CN
in other autoimmune diseases and bacterial infections, for
which the triple PRT assay is highly suitable.
MATERIALS AND METHODS
Case and control cohorts
Chinese SLE cases and controls. A Hong Kong Chinese SLE
patient cohort was recruited from three Hong Kong hospitals,
and control samples were obtained from the Hong Kong Red
Cross. In brief, patients and controls were all of self-reported
Chinese ethnicity living in Hong Kong, and patients met the
criteria of the American College of Rheumatology for SLE
diagnosis (51), with those with a definite diagnosis of lupus
nephritis designated by more than 0.5 g per day proteinuria
or cellular casts seen on urine microscopy. The study was
approved by the Institutional Review Board of the University
of Hong Kong and Hospital Authority, Hong Kong West
Cluster, New Territory West Cluster and Hong Kong East
Cluster. All patients and controls gave informed consent.
Caucasian SLE cases and controls. The UK SLE cohort was
obtained from the MRC/Kidney Research UK National DNA
Bank for glomerulonephritis. All individuals were between
the ages of 18 and 50 with a definite diagnosis of lupus nephri-
tis based on biopsy and on clinical and serological features
defined by the American College of Rheumatology. Control
individuals were obtained from the British 1958 Birth
Cohort, collected as part of an ongoing study following all
births in England, Scotland and Wales in 1 week in 1958
(www.b58cgene.sgul.ac.uk). This cohort is an expansion of a
data set previously shown to be appropriate for use as
UK-wide controls (52). This study was approved by the Cam-
bridge Local Research Ethics Committee and the Oversight
Committee of the KRUK DNA Bank.
Table 2. Logistic regression to test of independence of FCGR3B CN and FCGR2B-I232T risk in SLE
FCGR2B-I232T HK Chinese Caucasiana FCGR3B-CN HK Chinese Caucasian
TT versus IT/II 0,1 versus 2,3,4
1 P x2 0.142 0.0003 1 P x2 0.0003 0.017
2 P x2 0.211 0.001 2 P x2 0.0004 0.048
OR (95%CI) 1.28 (0.87–1.87) 2.72 (1.48–4.99) OR (95%CI) 1.67 (1.26–2.22) 1.55 (1.01–2.38)
Interaction
3 P x2 0.948 0.047
HK, Hong Kong; P x2, P-value of the Chi-square test statistic; OR, odds ratio; CI, confidence interval; 1,2,3 denote the order in which effects are adjusted for.
aCombined Caucasian group, comprised of UK Caucasian and Swedish Caucasian cohorts, in which the factor ‘group’ is used to take into account differences
between the cohorts prior to determining risk due to FCGR2B or FCGR3B.
Bold values show the statistical significance at the 95% level.
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The SwedishCaucasian SLE cohort comprised patients attend-
ing the Karolinska University Hospital, Solna, who fulfilled at
least 4 of the 1982 American College of Rheumatology (ACR)
classification criteria for SLE. Participants were examined in
person by a rheumatologist and their medical history and
medical records were reviewed. Blood samples were stored in
2708C after over-night fasting. The regional ethical boards and
the ethics review board at the Karolinska Institutet approved the
study. All patients and controls gave informed consent.
Caucasian vasculitis cases. The ANCA-associated vasculitis
cohort comprises subjects from three sources, all meeting
the Chapel Hill diagnostic criteria (53):
(1) The MRC/Kidney Research UK National DNA Bank for
Glomerulonephritis. Individuals were between the ages
of 18 and 70 years, were ANCA seropositive and had
biopsy-proven necrotizing glomerulonephritis.
(2) The UK vasculitis cohort 2 was recruited from nine
centres in the UK and comprised patients seropositive
for ANCA and/or with histological evidence of small
vessel vasculitis.
(3) Patients recruited from the University of Birmingham. All
individuals were ANCA seropositive with firm clinical
and/or histological evidence of vasculitis.
Vietnamese malaria cases and controls. Severemalaria patients
were recruited at the Hospital for Tropical Diseases (HTD) in Ho
Chi Minh City, Vietnam. Three hundred and forty-six patients
greater than 14 years of agewere enrolled as part of a randomized
controlled clinical trial of Artemether versus Quinine between
1991and1995 (54) anda further 71patientswere enrolled follow-
ing the same entry criteria from 2006 to 2008. Subjects were
defined as severe malaria patients if they had asexual forms of
P. falciparum on a peripheral-blood smear and had one or more
of the following as previously described (54); a score on the
GlasgowComaScale of,11, anaemia or jaundicewith a parasite
count of .100 000 per mm3 on a peripheral blood smear, renal
impairment, hypoglycaemia, hyper-parasitemia and/or systolic
blood pressure ,80 mmHg with cool extremities. The control
group comprised of 983 DNA samples extracted from the umbi-
lical cord blood of newborn babies born at HungVuongObstetric
Hospital, HCMC, in 2003–2007. All samples came from unre-
lated individuals who were ethnic Vietnamese Kinh, as assessed
by questionnaire. This study was approved by the ethical and
scientific committees of the Hospital for Tropical Diseases Ho
Chi Minh City.
Kenyan malaria cases and controls. The first group of severe
malaria cases comprised children admitted to the high depen-
dency unit at Kilifi District Hospital with P. falciparum
malaria, complicated by one or more clinical features of sever-
ity (coma, prostration, multiple seizures, severe malarial
anaemia or hyperparasitaemia), between 1992 and 1997 as
described previously (55). A second group of severe malaria
cases comprised children meeting the same criteria as children
in case group 1 who were admitted to the same hospital during
the period 2000–2008. The Kenyan control group was derived
from cord blood samples that were collected at Kilifi District
Hospital during the period 1992–2002.
Kenyan bacteraemia cases and controls. The cohort of bacter-
aemia cases were children (,13 years) admitted to Kilifi
District Hospital with blood-culture positive bacterial infec-
tion (Gram positive and negative) between 2003 and 2008.
The most frequent organisms were Streptococcus pneumoniae,
Salmonella typhi, Haemophilus influenzae and Escherichia
coli. The controls used for these cases were the same as
those used for the group of malarial cases. Ethical approval
for the collection of the Kenyan samples was given by the
Kenya Medical Research Institute (KEMRI) National Scienti-
fic Steering and Research Committees.
Paralogue ratio test conditions
Three PRT primer pairs, which each co-amplified products of
different lengths at two genomic locations, were used and
combined to determine FCGR3B CN. The primer pairs
PRT-2C3
′
/2A3
′
co-amplified products in the 3′-untranslated
region of FCGR2C and FCGR2A, PRT-3B/3A co-amplified
products in FCGR3B and FCGR3A and PRT-3(A+B)/c18
[based on a published assay (27)] amplified a region of the
same length in both FCGR3A and FCGR3B and a third
region in Chromosome 18 (4149307–4149392, hg18). Each
forward primer was labelled with HEX at the 5′ end. The
PCR reaction amplified 5–10 ng of genomic DNA using
Phusion Hot Start High Fidelity polymerase (Finnzymes)
with the HF buffer as described by the manufacturer with
the cycling conditions: 988C for 60 s, followed by 30 cycles
of denaturation at 988C for 10 s, annealing at the specified
temperature for 20s and elongation at 728C for a specified
time (below). A final hold at 728C for 7 min followed.
Control samples were run to allow normalization between
plates and wherever possible, plates comprised half of cases,
half of controls. The co-amplified products were added to
Hi-DiTM Formamide with the fluorescent GeneScanTM 500
LIZTM Size Standard (Applied Biosystems) and analysed on
an ABI 3730 × l DNA Analyzer/Sequencer (Applied Biosys-
tems). The HEX fluorescent peak areas corresponding to the
two products were recorded by GeneMapper 4.0 software
(Applied Biosystems).
PRT pair Primer Annealing (8C) Elongation (s) Product size (bp)
PRT-2C3′/2A3′ FOR 5′-CTTCATGAATTGCGCCTCAG 67 20 FCGR2C 274
REV 5′-GCTAGAGGCCAGAAGTTCGAG FCGR2A 279
PRT-3A/3B FOR 5′-GATGTCCACGAATCCACTGG 65 30 FCGR3B 304
REV 5′-GACAGGAACTCTTTACCTTCCTCG FCGR3A 296
PRT-3(A+B)/c18 FOR 5′-TGCCCTTCATGATCTGGCC 60 5 FCGR3B/3A 75
REV 5′-TGAGTTCAAGAAAGCAGTTTG Chr18 86
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CN designation by data clustering
The relative amounts of the co-amplified products produced in
each PRT reaction were determined for each sample, and rela-
tive underlying diploid gene CN was inferred. In order to
improve the discrimination between groups of individuals
with different relative gene CNs, the FCGR3B/FCGR3A
product result was plotted against FCGR2C3
′
/ FCGR2A3
′
,
since FCGR2C and FCGR3B were expected to have the
same CN. Clusters comprising a relative product amount of
approximately 0.5, 1 and 1.5 for both PRT assays were desig-
nated using the ‘mclust’ package from Bioconductor (56,57).
A Gaussian mixture model using an expectation-maximization
(EM) algorithm was generated, and model-based cluster analy-
sis was applied to group the data. The algorithm was con-
strained by filtering out all the cases where one or more of
the intensities were zero or missing, and then the expected
number of clusters was set to 3. The clusters were specified
to be ellipsoidal with variable volume but constant shape.
Multiple plates were normalized with controls and combined.
The relative product amounts of 0.5, 1 and 1.5 corresponded to
FCGR3B:FCGR3A diploid gene CN of 1:2, 2:2 and 3:2,
respectively. CN combinations which were rare, or which
formed clusters too diffuse to be called by the clustering algor-
ithm, were called by two researchers blinded to cohort follow-
ing further discrimination by plotting the FCGR3B/FCGR3A
result against the FCGR3(A+B)/Chr18 result. These clusters
represented the FCGR3B:FCGR3A diploid gene CN of 0:2,
4:2, 2:3, 2:1, 3:1 and 1:3, and assumed only one CN variable
event per chromosome. FCGR3B:FCGR3A gene CN of 1:1
and 3:3 could not be discriminated from FCGR3B:FCGR3A
of 2:2 due to the variability in the PRT-3(A+B)/Chr18 assay.
When adjacent regions amplified by PRT varied in CN
together, the locations were assumed to be part of a single
CN region. The identified regions (CNR1, CNR2, CNR3)
were compared with CN regions described by a previous
study using MLPA with multiple probes in each gene in the
low-affinity FCGR locus (6,20), and the estimated ranges of
CNR1 and CNR2 were extended to include surrounding
gene areas based on similarities to the previous regions.
For a more detailed description of CNV assignment, see
Supplementary Material.
SNP typing
The primers for the FCGR2B-specific long-range PCR were
those used previously (58). Following cleanup of PCR pro-
ducts by ExoSAP-IT (GE), SNP typing was performed using
a custom TaqMan Human SNP Genotyping Assay (Applied
Biosystems). For FCGR2A and FCGR3A SNP typing, a pre-
designed TaqMan Human SNP Genotyping Assay (Applied
Biosystems) was used in accordance with the manufacturer’s
protocol. Fluorescence detection for allelic discrimination
was performed on an Applied Biosystems 7500. Sequence
detection system software (Applied Biosystems) was used to
plot results and automatically call genotypes dependent on flu-
orescence intensities of the VIC and FAM reporter dyes.
Statistics
Association. The association of CN or SNP genotype with
disease was tested by a Fisher’s exact test or Chi-square
contingency test where appropriate using GraphPad Prism.
Meta-analysis was performed using Stats Direct software,
with a random effects model to allow for variation between
studies.
Linkage disequilibrium. The LD between SNPs or between
SNPs and CNV was determined both at the genotype and hap-
lotype levels. All samples used were from normal individuals
from the control cohorts (UK Caucasian, Swedish Caucasian,
Kenyan, Vietnamese and Hong Kong Chinese) used in the
association studies. At the genotype level, LD between SNPs
was determined by correlation, with the P-value to reject the
null hypothesis that Pearson’s r ¼ 0 determined using Graph-
Pad Prism. LD between a SNP and CNV was determined at
the genotype level by a covariance test between SNP and
CNV genotype in R.
To determine LD at the haplotype level, phase was inferred.
For two SNPs, haplotype phase in both SNPs was estimated
using maximum likelihood in the R genetics function
LD(data), which derived the LD measures D, D′ and r2,
using standard equations, as well as the chi-square statistic
for linkage equilibrium. A D′ over 0.25 was taken to show
an appreciable level of LD between two loci. For a SNP and
CNV, phased haplotypes were estimated using an maximum
likelihood, in which the 3 × 5 table of genotypes ([0,1,2,3,4]
CN × [aa aA AA] SNP genotypes) was iteratively mapped
onto a 3 × 2 table of haplotypes ([0,1,2] CN × [a, A] SNP
alleles). Hardy–Weinberg equilibrium was assumed. D′ and
r2 were then determined using the same method as for two
di-allelic loci, with LD for 0,1 CN versus 2 CN, 1,2 versus
0 and 0,2 versus 1 haplotype combinations calculated indivi-
dually.
To determine which genotype combination was elevated
due to LD, observed numbers of each diplotype combination
were compared with the estimated numbers derived from the
frequency of each individual diplotype.
Independence of factors. The independence of the SNP and
CNV was tested by logistic regression with approximation to
a general linear model (binomial family) in R, using
ANOVA to test the effect of the SNP, followed by the effect
of the CNV, then their interaction. The order of testing of
SNP and CNV was then reversed. To combine the two Cauca-
sian groups, a third factor was added which removed the effect
of the differences between the groups prior to testing for the
effect of the SNP of CNV. The OR for the risk due to each
factor was expressed with 95% CIs.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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